Category: glioblastoma
-
™E Pharma Announces Oral Presentation of NOX-A12 GLORIA Phase 1/2 Trial in Glioblastoma at ESMO Congress 2024 By Investing.com
•
Berlin-(Business):™E Pharma NV (Euronext Growth Paris: AL™E), A clinical-stage biotechnology company focused on developing novel therapies to treat cancer by targeting the tumor environ- ment (E™), today announced that an abstract including results from the NOX-A12 GLORIA Phase 1/2 trial in first-line brain cancer (glioblastoma) has been selected for presentation…
-
IN8bio shares target left unchanged from Laidlaw on glioblastoma study By Investing.com
•
(NASDAQ:INAB) IN8bio Inc. (NASDAQ:INAB) on Monday received a Buy rating and a $7.50 stock target from Laidlaw, following the latest presentation of clinical study results. Over the weekend, the company updated its Phase 1 study of INB-200 in the treatment of glioblastoma (GBM) at the American Society of Clinical Oncology…